Activated mature T cells induce various inhibitory receptors implicated in maintaining peripheral tolerance in response to the trans-acting ligands. Interestingly, paired Ig-like receptor (PIR)-B, an inhibitory MHC class I receptor on B cells and myeloid cells, could be involved in regulating early T cell development because epitope for PIR is detected on pre-thymic T/NK progenitors but not on thymocytes or mature T cells. We hypothesized that PIR-B is not only a regulator for T cell development but is also detrimental if expressed on mature T cells. Here we demonstrated, using PIR-B-deficient fetuses, that PIR-B is indeed expressed on the T cell progenitors but failed to identify its distinctive roles in the development. Forced expression of PIR-B in thymocytes and mature T cells also resulted in no abnormalities in development. However, upon antigenic or allogeneic stimulation, peripheral T cells with the ectopic PIR-B showed reduced T h type 1 responses due to the suppression of proximal TCR signaling by constitutive binding of PIR-B to MHC class I on the same cell surface. Our findings suggest that T cell expression of PIR-B with the cis-interacting MHC class I is strictly prohibited in periphery so as to secure prompt immune responses.
Introduction
It is of fundamental importance to elucidate the whole mechanisms for T cell development and its functional regulation in the periphery in order to control immune responses to pathogens, tumor cells and transplants while avoiding autoimmunity. Recent studies have revealed the crucial roles of T cell regulatory receptors with the inhibitory cytoplasmic motifs in maintaining peripheral tolerance. These include CTLA-4 (1) programmed death-1 (PD-1) (2), CD5 (3), inhibitory killer Iglike receptors (4, 5) , Ly49 (6, 7), CD94/NKG2 (8) and leukocyte Ig-like receptor (LILR) B1 (also known as ILT2/LIR1/ MIR7/CD85j) (9) (10) (11) . The most prominent examples are two major regulators of the CD28 family, CTLA-4 and PD-1, which are both crucial for controlling T cell activation (1, 2) . CTLA-4 is expressed constitutively on naturally occurring forkhead box P3 (Foxp3) + CD25 + CD4 + regulatory T cells (Tregs), while on other T cell subsets its expression is induced in an activation-dependent manner. CTLA-4 interacts with the trans-interacting ligands, CD80 and CD86, on antigenpresenting cells (APCs) to deliver a negative co-stimulatory signal to activated T cells, inhibiting TCR-and CD28-mediated signal transduction (1, 12) , whereas its constitutive expression on Tregs is critical for the down-regulation of CD80/ 86 on dendritic cells (DCs) through an as yet unidentified mechanism (13) . PD-1, on the other hand, is expressed by activated CD4
+ and CD8 + peripheral T cells (2, 14) , binds to the trans ligands PD-L1/2 expressed on APCs and non-lymphoid tissues and is implicated also in maintaining peripheral tolerance. In contrast to the wealth of evidence for the indispensable roles of T cell inhibitory receptors in maintaining peripheral tolerance, their involvement in pre-, intra-and extrathymic development remains elusive.
The paired Ig-like receptor (PIR)-B (15, 16 ) is a murine inhibitory receptor for MHC class I molecules (MHC-I) (17) , whose human counterpart is considered to be LILRB1/2 (17) (18) (19) . PIR-B is unique in that it has potential for regulating the pre/intra/extra-thymic development of T lineage cells and may also possess a hidden potential to modulate T cell functions in the periphery. Thus, PIR-B is expressed on B cells, DCs and other myeloid cells, but not on mature T cells or NK cells (20) (21) (22) . Although thymocytes and peripheral T cells from adult mice do not show expression of either PIR-B or its activating isoform PIR-A (20) , recently one group of ours, Masuda et al. (23) , found that an epitope for PIR is expressed on pre-thymic progenitors restricted to T/NK/DC lineage in the fetal liver but it begins to be down-regulated at the CD44 + CD25 À double-negative (DN) 1 stage of the fetal thymus. Thus, PIR-B and/or PIR-A expression takes place in pre-thymic, early T lineage cells but suddenly disappears after the intra-thymic stage.
Since we previously observed that the development of adult thymocytes and mature peripheral T cells does not show gross abnormalities in PIR-B-deficient (Pirb À/À ) mice, the observations of Masuda et al. (23) were surprising and prompted us to examine in more detail whether the early-expressed PIR could be PIR-B, PIR-A or both. Moreover, we were also interested in determining what happens in T cells when the expression of PIR-B is forced and continues in such early T lineage cells as well as at later stages such as in mature T cells. Our postulation was that PIR-B is not only an intrinsic regulatory receptor for the thymic development of T cells but also a harmful molecule if expressed in mature T cells for maintaining peripheral tolerance. In this study, we will provide evidence for the latter notion, but we failed to obtain any suggestive data for the former PIR-B's role in development.
Materials and methods

Mice
C57BL/6 (B6) and BALB/c mice were purchased from Charles River (Tokyo, Japan). C57BL/6 3 DBA/2 F 1 (BDF 1 ) mice were purchased from CLEA Japan (Tokyo, Japan). Pirb À/À 129/B6 mice (24) were backcrossed onto B6 for 12 generations. Mice were maintained and bred in the Institute for Experimental Animals (Tohoku University), an environmentally controlled and specific pathogen-free facility, according to the guidelines for experimental animals defined by the facility, and animal protocols were reviewed and approved by the Tohoku University Animal Studies Committee. All experiments were performed on 6-to 13-week old agematched male or female mice.
Co-culture with a fetal thymic lobe and stromal cells
To assess the potential of single cells as to the ability to give rise to T cells, single cells were individually cultured for 10 days with a fetal thymic lobe which had been treated with deoxyguanosine, as described previously (25) . T cell generation was determined by examining the CD3 expression on generated cells. To assess the potential of single cells for B cell generation, cells were individually cultured on a monolayer of stromal cell line TSt-4 (26) for 10 days, and B cell generation was determined by examining the CD19 expression.
Generation of transgenic mice
The cDNA segment coding for B6 PIR-B was amplified by PCR using primers containing BglII sites and a Kozak sequence, integrated into pT7blue vector, amplified, digested with BglII and integrated into the BamHI site of the plck vector (a gift from Toshinori Nakayama, Chiba University, Chiba, Japan). The vector was linealized by digestion with Not I and the resulting 8.6-kb fragment containing the lck promoter, PIR-B, and hGH enhancer was purified by agarose gel electrophoresis. We employed a standard protocol for obtaining transgenic (Tg) mouse lines using host embryos from B6 or BDF 1 mice. DNA samples were isolated from the tail tips of pups, digested with EcoRI and subjected to Southern blot analysis using a PIR-B cDNA probe (nucleotides 2179-2525) (15) to identify Tg mice having a 2.9-kb DNA fragment that hybridized to the probe. The Tg mice were intercrossed to establish homozygous Tg lines, whose genotypes were confirmed by real-time PCR analysis for the Pirb gene segment. Five independent Tg lines, one of which has the B6 genetic background (Tg1, H-2 b ), the other lines being BDF 1 (Tg2-5). Tg2 mice were backcrossed onto B6 genetic background for five to eight generations.
Reagents, antibodies and flow cytometry
The following mouse-specific mAbs were used: FITC-, PE-, biotin-or Alexa 647-conjugated anti-CD3 (145-2C11; BD Biosciences, San Jose, CA, USA), anti-CD4 (GK4; eBioscience, San Diego, CA, USA), anti-CD8 (53-6.7; BD Biosciences), anti-CD25 (PC61; eBioscience), anti-CD44 (IM7; BD Biosciences), anti-CD62L (MEL-14; BD Biosciences), anti-CD69 (H1.2F3; BD Biosciences), anti-PIR-A/B (6C1; BD Biosciences), anti-B220 (RA3-6B2; BD Biosciences) and anti-Foxp3 (150D; BioLegend, San Diego, CA, USA). Streptavidin-tricolor (Caltag, Burlingame, CA, USA), streptavidinallophycocyanin (BioLegend), streptavidin-PE/Cy5 (BioLegend) and streptavidin-PerCP/Cy5.5 (BD Biosciences) were used for detection of biotinylated antibodies. For intracellular Foxp3 staining, cells were fixed and permeabilized with a Cytofix/Cytoperm Plus Fixation/Permeabilization Kit (BD Biosciences) and stained with Alexa 647-labeled anti-Foxp3 mAbs. Flow cytometric analysis was performed using a FACS LSR or FACSCalibur (BD Biosciences) and FlowJo (TreeStar, Ashland, OR, USA).
Magnetic cell sorting
For magnetic cell sorting (MACS), biotinylated anti-CD49b mAb (DX5, BD Biosciences), anti-CD19 mAb (1D3; BD Biosciences), anti-CD11b mAb (M1/70; BioLegend) and magnetic bead-labeled anti-CD4, CD8, Thy1 antibodies (Miltenyi Biotech, Bergisch Gladbanch, Germany) were used. For sorting of cells with biotinylated antibodies, magnetic beadlabeled streptavidin (Miltenyi Biotech) was used. Splenocytes from wild-type and Tg mice were treated with 0.144 M ammonium chloride to remove RBCs, reacted with magnetic beadlabeled antibodies as indicated and then separated with an automated magnetic cell sorter (autoMACSpro, Miltenyi Biotech). 16 h, and then proliferative responses were measured. The supernatant was collected after 72-h stimulation and subjected to measurement for IL-2 and IFN-c by ELISA. For investigation of humoral responses, mice were immunized with 10 lg per head OVA in CFA intra-dermally into dorsal skin. Secondary challenge with 10 lg per head OVA in incomplete Freund's adjuvant was performed 3 weeks after the primary immunization, and blood samples were taken every week. The antibody titers of OVA were measured by ELISA as described (24) .
Induction of graft-versus-host response
Splenic Thy1
+ cells were transferred to six Gy-irradiated 8-to 12-week old recipient C57BL/6 3 BALB/c F 1 (CB6F 1 ) mice via a tail vein. The survival of mice was monitored every 12 h after the transfer. For the measurement of IFN-c production, spleen cells were harvested and pooled from three or four recipient mice per group at 4-7 days after transplantation. Spleen cells (1 3 10 5 ) were incubated with T celldepleted, CD5-negative donor splenocytes (4 3 10 5 cells) from syngeneic CB6F 1 mice or allogeneic B6 mice for 24 h at 37°C on 96-well round-bottom plates (Corning). The T cell depletion was performed with autoMACS. The IFN-c concentrations in the supernatant were measured with ELISA Max Set Standard (BioLegend) according to the manufacturer's protocol.
Immunoblotting
Thy1
+ cells were purified from splenocytes with autoMACS after depleting CD11b + , DX5 + and CD19 + cells. The cells and thymocytes were incubated with 1 lg ml À1 anti-CD3e mAb (145-2C1) for 20 min at 4°C, cross-linked with 1 lg ml À1 polyclonal goat anti-hamster IgG for 5 min at 37°C, lysed with lysis buffer [20 mM Tris-HCl, 1 mM EDTA, 1% NP-40, 150 mM NaCl or 0.75% Briji-97 (Sigma-Aldrich, St Louis, MO, USA), 150 mM HEPES (pH 7.4), 50 mM NaCl and 10% glycerol] containing protease inhibitors (Protease Inhibitor Cocktail, Sigma-Aldrich) and 2 mM NaV 3 O 4 (Sigma-Aldrich) and spun down to remove nuclear materials, and the resulting supernatant was subjected to immunoblot analysis. The samples were reacted with rat anti-PIR-A/B (6C1), anti-CD3f (6B10; Zymed Laboratories, South San Francisco, CA, USA), anti-Zap70 (1E7.2; eBioscience), antilinker of activation of T cell (LAT) (Upstate Biotechnology, Lake Placid, NY, USA) or anti-phospholipase C (PLC)-c1 (Cell Signaling Technology, Danvers, MA, USA) followed by immunoprecipitation with protein G-conjugated Sepharose (GE Healthcare, Piscataway, NJ, USA). The precipitated samples were separated by SDS-PAGE under reducing conditions, blotted onto polyvinylidene difluoride (Invitrogen) membranes, reacted with biotin-labeled anti-phosphotyrosine (4G10, Upstate Biotechnology), reacted with streptavidin-HRP (GE Healthcare) and finally visualized with ECL system (GE Healthcare). The membranes were then stripped with a stripping buffer [62.5 mM Tris-HCl (pH 6.8), 100 mM 2-mercaptoethanol and 2% SDS] and re-blotted with the following antibodies: anti-src homology 2-containing tyrosine phosphatase (SHP)-1 (sc-287, Santa Cruz Biotechnology, Santa Cruz, CA, USA), biotin-labeled anti-PIR-A/B, antiCD3f, biotin-labeled anti-Zap70, anti-LAT or anti-PLC-c1 and then reacted with HRP-labeled secondary antibodies or streptavidin-HRP. 
Statistical analysis
Statistical analyses were performed using two-way analysis of variance, Student's t-test or log-rank test. P < 0.05 is considered as statistically significant.
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Results
Pre-thymic and early intra-thymic T cell development is not impaired in Pirb
À/À fetuses PIR expression was recently demonstrated on pre-thymic T cell progenitors in early fetal period (23) . We examined first whether the pre-thymic T progenitors are normally generated in Pirb À/À fetuses. Fetal liver cells of 13 days post-coitum (d.p.c.) wild-type and Pirb À/À mice were gated with a Lin À ckit + and tested for IL-7 receptor (IL-7R) and PIR expression. As shown in Fig. 1(A were examined for T and B cell potential at the single-cell level. We found that the frequencies of progenitors generating B cells and those generating T cells were not altered in the absence of PIR-B (Fig. 1B) , indicating that pre-thymic T cell progenitors are normally generated in the fetal liver of Pirb À/À mice. The data in Fig. 1 (B) may also indicate that the loss of PIR + cells in fetal liver of Pirb À/À mice shown in Fig. 1(A) is not due to the absence of pre-thymic T cell progenitors. Therefore, it is likely that pre-thymic T cell progenitors exclusively express PIR-B, but not PIR-A. Immunohistochemical examination of the number of T cell progenitors migrating to the perithymic area of 11 d.p.c. Pirb À/À fetuses suggested normal migration of T cell progenitors to the thymus in the mutant mice (data not shown). In addition, early intra-thymic T cell development was not impaired in Pirb À/À fetuses, as assessed by CD44 and CD25 staining of thymocytes from 13 d.p.c. wild-type and Pirb À/À fetuses (Fig. 1C) . We also examined whether the extra-thymic T cell development is impaired or not in Pirb À/À fetuses by staining cells from thymuses, para-aortic lymph nodes, spleens and intestines of 15 d.p.c. wild-type and Pirb À/À fetuses with anti-Thy1 and anti-c-kit but did not observe obvious alterations (data not shown). These results indicate that pre-thymic, extra-thymic and early intra-thymic T cell development is not grossly impaired in Pirb À/À fetuses.
Tg PIR-B expression on thymocytes and peripheral T cells does not affect cellularity
To determine whether forced expression of PIR-B on thymocytes and peripheral T cells could modify T cell development and function, we generated Tg mice exhibiting T cell-specific expression of PIR-B driven by the proximal promoter of the lck gene. Flow cytometric analysis revealed that all the five independent Tg lines exhibited robust expression of PIR-B on adult thymocytes and splenic CD3 + cells (Fig. 2A) . The Tg1 line on B6 background or Tg2 line, which had been backcrossed with B6 for five to eight generations, was mainly characterized. The total cell numbers of adult thymocytes and splenocytes in Tg1 mice were comparable to those in wild-type mice (thymocytes, 1.55 6 0. (28) . Interestingly, PIR + pre-thymic T lineage cells become DN1 cells after their homing to the thymus but simultaneously begin down-regulation of PIR (23) . The proximal lck promoter begins to be active at the DN1 stage and persists thereafter through the mature peripheral T cell stage (29) , suggesting that transcription of the Pirb transgene starts at DN1. We found that a substantial proportion of thymocytes exhibited PIR expression on Tg1 and Tg2, while B6 thymocytes showed very low or negligible PIR expression ( Fig. 2A) . We found no marked alterations in the size of each DN subsets (Fig. 2B) . The size of each later thymic developmental stages subdivided by CD4 and CD8 expression was comparable between Tg2 and wild-type mice (Fig. 2C) .
Stimulation of TCR of thymic CD4 + CD8 + double-positive (DP) cells is a critical step for positive/negative selection of self-reactive TCR-bearing cells (30, 31) . If these DP cells were stimulated exceedingly through the TCR-CD3 complex such as with anti-CD3 antibodies, they would be eliminated via the apoptotic process. We supposed that the forced expression of PIR-B on DP thymocytes could be suppressive for the negative selection process. We administered anti-CD3 antibodies to B6 and Tg1 mice and measured their thymic DP cell populations after 48 h by flow cytometry. The stimulation induced a significant reduction in the DP subsets of B6 and Tg mice compared with that in those stimulated with an isotype control, but the magnitude of the reduction was not statistically different between them (Supplementary Figure S1 figure) . A population of splenic CD3 + lymphocytes and splenic CD4 + and CD8 + T cell compartments were not significantly different in Tg1 mice compared with B6 mice (data not shown). Also, the expression levels of various surface markers, including activation markers such as CD69, CD44, CD62L and Fas, on splenic Thy1 + T cells were not different between Tg1 and B6 mice (data not shown). These results indicate that the forced expression of PIR-B on peripheral mature T cells has no influence on their compartments. The size of the CD25 + Foxp3 + Treg population was not altered significantly by Pirb transgene expression in the splenocytes (data not shown). Taking these data together, we concluded that the forced and continuous PIR-B expression by the proximal lck promoter in thymic and peripheral T cells does not influence the gross T cell development or their negative selection or Treg development under non-pathogenic conditions. (18, 22) , and indirectly leads to augmented allogeneic or anti-tumor responses of CD4 + and CD8
Peripheral T cell responses are attenuated in Tg mice
PIR-B deletion in mice results in various up-regulated or perturbed responses in cells naturally expressing PIR-B, such as B cells, mast cells and DCs
+ T cells that have received antigen presentation by Pirb À/À DCs (17, 19) . Thus, we were next interested in determining whether the forced and continuous expression of PIR-B could have any direct regulatory role in peripheral T cells in several experimental settings. We first compared the proliferative responses of peripheral Thy1 + T cells from B6 and Tg1 mice upon anti-CD3 stimulation in vitro and found the reduced proliferation of Tg T cells after 24-h culture, but not at 48-h culture, with different concentrations of anti-CD3 antibodies (Fig. 3A) . Likewise, we observed significantly reduced production of IFN-c by T cells stimulated with anti-CD3 or anti-CD3 plus anti-CD28 antibodies and cultured for 24 and 48 h, but not by those cultured for 72 h (Fig. 3B) . These results suggest that stimulation of T cells from PIR-B Tg mice can induce the reduced proliferation and decreased production of IFN-c in an earlier phase after stimulation, but not in a prolonged culture in vitro. When we measured the expression of CD69, an activation marker, on resting or anti-CD3-stimulated CD4 + or CD8 + T cells from B6 and Tg1 mice by flow cytometry, we observed reduced proportions of CD69 + cells among CD4 + and CD8 + Tg T cells (Fig. 3C) , consistent with the reduced responsiveness of Tg T cells to CD3 stimulation.
Next, we examined T cell proliferation in an MLR. CFSElabeled, Thy1
+ splenic T cells from Tg1 mice (H-2 b ) were co-cultured in vitro for 72 h with bone marrow-derived DCs from BALB/c mice (H-2 d ) and monitored as to their proliferation by flow cytometry. As shown in Fig. 3(D) , we found a significantly reduced number of proliferating cells from Tg mice. These results indicate that the anti-CD3-and allo-MHCinduced proliferative responses of splenic T cells in vitro are suppressed by the forced PIR-B expression.
Effector/memory T cells are attenuated in PIR-B Tg mice in vivo
We then looked for possible reductions in the antigenspecific T cell responses of Tg mice such as upon OVA immunization. To this end, we first checked the effector/ memory T cell population in Tg mice by flow cytometry with CD62L and CD44 staining. We found comparable numbers of CD62L high CD44 low naive T cells and CD62L low CD44 high effector/memory T cells in both B6 and Tg1 mice or Tg2 mice ( Fig. 4A and Supplementary Figure S3 , available at International Immunology Online). To further examine the development of effector T cells in Tg mice after immunization with T-dependent antigen, B6 and Tg1 mice were immunized with OVA. CD4 + T cells were isolated from draining lymph nodes at day 6, re-stimulated in vitro with OVA, and then assessed for their proliferation and production of cytokines. The proliferative response (Fig. 4B ) and IL-2 production (Fig. 4C, left) were comparable between OVA-primed T cells from B6 and Tg1 mice, possibly due to saturation of the proliferation at 48 h, while IFN-c production was significantly reduced in those from Tg1 mice (Fig. 4C, right) . IL-4 production was under the detectable limit (data not shown), confirming that the T h 1 response was dominant with this OVA immunization. These results suggest that antigen-primed CD4 + T h 1 cells from Tg mice can proliferate normally in recall response in vitro, but their IFN-c production is reduced. The serum titers of total anti-OVA IgG and IgG1 were not remarkably different, whereas the anti-OVA IgG2c titer in Tg1 mice was reduced in Tg1 mice (Fig. 4D) . These results suggest that the early responses of T cell priming are suppressed by transgene-derived PIR-B.
IFN-c production is reduced in graft-versus-host settings
An acute graft-versus-host (GVH) response is induced by strong allogeneic responses involving activated donor T h 1 cells and cytotoxic T cells against recipient tissues. Based on our observation of reduced T cell proliferation and IFN-c production, we examined whether donor Thy1 ). Four to seven days after cell transfer, splenocytes from the recipient CB6F 1 mice, the vast majority of which would be substituted by cells of the donor Tg origin during the GVH response, were stimulated for 24 h in vitro with T cell-depleted allogeneic (recipient CB6F 1 ) splenocytes or syngeneic (donor B6) splenocytes as a control, and then supernatants were collected and subjected to determination of the IFN-c content. The IFN-c production was found to be more reduced in splenocytes from CB6F 1 mice that had received PIR-B Tg Thy1
+ cells than in those that had received non-Tg B6 cells (Fig. 5A) . However, we did not observe obvious alterations in the lethality to the animals during such GVH responses (Fig. 5B) , indicating that Tg splenic T cells provoke less severe early responses during induction of the GVH reaction due to the reduced production of IFN-c by the donor PIR-B + T cells, but that the survival of the mice is not significantly affected when they receive PIR-B + Thy1 + cells.
PIR-B constitutively inhibits TCR signaling in Tg T cells
In the case of intrinsic PIR-B on mast cells (18) , DCs (19) and osteoclasts (32), PIR-B constitutively binds to MHC-I on the same cells in cis and is constitutively tyrosine phosphorylated at its immunoreceptor tyrosine-based inhibitory motif and associates with SHP-1, thereby triggering inhibitory signaling (20, (33) (34) (35) (36) . To determine whether forced expression of PIR-B also constitutes the cis interaction with MHC-I and delivers the constitutive inhibitory signal to T cells, we examined the membrane proximal events related to PIR-B on thymic and peripheral T cells. Figure 6 (A) shows that PIR-B expressed on thymocytes and splenic T cells was constitutively phosphotyrosylated and recruited SHP-1. On the other hand, in comparison with macrophages, PIR-B in thymocytes of Tg mice was less phosphorylated but recruiting more SHP-1 (Fig. 6A) . In T cells, no clear binding partner for SHP-1 has been identified (37), while many inhibitory receptors associate with SHP-1 in macrophages. Therefore, it is possible that the recruitment of SHP-1 to the phosphorylated PIR-B was increased in Tg thymocytes. Next, we performed FRET analysis of PIR-B and MHC-I bound to fluorescence-labeled mAbs to determine the 
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proximity between the two cell surface molecules. Although it is conceivable that PIR-B can interact in trans with MHC-I on the other cells, our FRET analysis revealed a significant FRET effect between PIR-B and H-2 K b /D b heavy chain (Fig. 6B) , strongly suggesting that PIR-B and MHC-I associate on the same cells, even in the resting state, as is the case for myeloid cells (18, 19, 32) .
We examined intracellular signaling events immediately downstream of the interaction between PIR-B and MHC-I on the cell surface. CD3 stimulation yielded less efficient phosphorylation of TCR signaling molecules, particularly Zap70, LAT and PLC-c1, in the presence of phosphotyrosylated PIR-B (Fig. 6C) . However, the tyrosine phosphorylation of PIR-B per se was not augmented upon CD3 stimulation (Fig. 6C, top panel) . Our previous studies also showed that the phosphorylation status of PIR-B is slightly increased after stimulation in mast cells or B cells (18, 24) . These results indicate that PIR-B mainly delivers the constitutive inhibitory signal to immune cells in the steady state, and the upstream events of the canonical TCR signaling are inhibited by PIR-B, which is constitutively tyrosine phosphorylated and recruits SHP-1. We thus conclude that the forced and continuous expression of PIR-B renders T cells less sensitive to stimulation via TCR, which may be the reason why T h 1 cell development and IFN-c production were suppressed in an early responses to antigenic as well as allogeneic stimuli.
Discussion
In this study, we aimed at clarifying whether PIR-B has the potential to regulate the early T cell development and any hidden harmful function in peripheral T cells. As a consequence, early T cell development was not distorted by the PIR-B deletion or its ectopic expression, implying that the PIR-B inhibitory machinery does not have any obvious role in T cell development. However, we found that the early responses to a T-dependent antigen and allogeneic cells were significantly reduced by the constitutive inhibition established ectopically. Thus, unlike B cells and myeloid cells, expression of inhibitory receptors in T cells is basically activation dependent, while that of the receptors with a possibility to suppress the signal constitutively is strictly prohibited in periphery so as to secure prompt and sufficient responses to external stimuli.
Then, why do B cells and myeloid cells possess the system for constitutive inhibition while T cells do not? It is conceivable that the activation threshold for B cells and myeloid cells, including DCs, must be controlled continuously by a series of inhibitory receptors because their 'danger signal' receptors such as B cell receptor and Toll-like receptors so frequently and directly bind to exogenous materials that they easily evoke activation signals in the absence of such a constitutive inhibitory system. On the other hand, T cells in periphery had been well educated by the thymic environment not to respond promiscuously to exogenous substrates without the antigen presentation by APCs that had already been activated through overcoming the primary threshold set by various inhibitory receptors. In fact, our experiments showed that T cell responses were retarded and attenuated, particularly in the T h 1 arms, under the PIR-B's constitutive inhibition set ectopically, suggesting that T h 1 cells need to be activated promptly upon antigenic stimuli. When we had such a constitutive inhibitory system in our T cells, our immune system could not respond quickly to pathogens due to the retarded T h 1 responses. Thus, the constitutive inhibitory signal like that of PIR-B should be used differently in T cells and B/myeloid cells in pursuing adequate immune responses. Given that murine PIR-B and human LILRB1/2 are orthologs genetically and functionally (9, 10, 17, 20, 22) and that LILRB1 has been shown to bind H-2 K b /D b in LILRB1 Tg mice under the control of human CD2 promoter (11) , it is interesting to compare the phenotypes of LILRB1 Tg mice with ubiquitous transgene expression (11) and those of our T cellspecific Tg mice. Interestingly, both LILRB1 Tg and PIR-B Tg mice show suppressed proximal TCR signal and defects in mounting T h 1 responses. In LILRB1 Tg mice, robustly suppressed allo-immune responses were observed, where skin allografts survived for a long period, which is associated with reduced cytotoxic T cell activity (11) . In the present study, we observed reduced IFN-c production by PIR-B Tg T cells upon the anti-OVA recall response. In addition, the acute GVH response induced by the transfer of donor PIR-B Tg Thy1
+ splenocytes into recipient mice resulted in less pronounced IFN-c production but not prolonged survival of the recipients, indicating that the GVH reaction was less severe and did not influence the lethality. It is conceivable that the differences in PIR-B and LILRB1 Tg mice in terms of the severity could be due in part to a difference in the level of receptor expression on T cells and/or to the different binding affinities for the ligands, i.e. H-2 molecules.
In conclusion, under natural conditions, PIR-B expression should be strictly suppressed so as to allow efficient T cell priming. Our present study establishes the importance of the pertinent regulation of PIR-B expression restricted to B cells and myeloid cells, but not to T cells or NK cells, so as to maintain the level of responsiveness toward antigens presented by APCs and to prohibit the promiscuous activation of B cells and myeloid cells. For T cells, such a constitutive negative regulation is harmful to ensure prompt activation upon antigenic stimulation.
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